First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

NCT05828459 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancy
Solid Tumor

Interventions

DRUG: OT-A201
DRUG: IMids
DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: TBD Compound

Sponsor

Onward Therapeutics